September 13, 2012
A new study on Breast Cancer is now available. According to news originating from Barcelona, Spain, by NewsRx correspondents, research stated, “Aromatase inhibitor (AI)-related bone loss is associated with increased fracture rates. Vitamin D might play a role in minimising this effect.” Our news journalists obtained a quote from the research from IMIM, “We hypothesised that 25-hydroxy-vitamin D concentrations [25(OH)D] after 3 months supplementation might relate to bone loss after 1 year on AI therapy. We conducted a prospective cohort study from January 2006 to December 2011 of a consecutive sample of women initiating AI […]
